Brazil
  • pt
  • en
    • Search

    GNOM

    Genomics & Biotechnology ETF

    Invest in GNOM

    Reasons to Consider GNOM

    High Growth Potential

    Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1

    Structural Tailwinds

    Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 47% compound annual growth rate from 2022-2028.2

    Targeted Exposure

    GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

    1International Society for Cell and Gene Therapy, Feb 2019
    2Evaluate Pharma, Nov 2023

    Key Information As of 11/20/24

    Inception Date 04/05/19
    Total Expense Ratio 0.50%
    Net Assets $71.73 million
    NAV $9.81

    ETF Summary

    The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

    ETF Objective

    The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

    Trading Details As of 11/20/24

    Ticker GNOM
    B3 Trading Code BGNO39
    Bloomberg Index Ticker SOLGNOM
    CUSIP 37954Y434
    ISIN US37954Y4347
    Primary Exchange Nasdaq
    Shares Outstanding 7,310,000
    Number of Holdings 44
    30-Day Median Bid-Ask Spread 0.19%

    Distributions As of 11/20/24

    30-Day SEC Yield -0.16%
    Distribution Frequency Semi-Annually
     Distribution History

    ETF Prices As of 11/20/24

    NAV $9.81 Daily Change $0.07 0.72%
    Market Price $9.82 Daily Change $0.06 0.61%

    Performance History

    Premium Discount Chart
    Cumulative Returns (as of 10/31/24)
    		1 Month 6 Months YTD 12 Months 24 Months Since Inception Inception Date
    Return GNOM -7.83% 5.20% -10.46% 16.93% -22.95% -32.09% 04/05/19
    Returns (as of 11/20/24)
    		Return GNOM Return Index
    Since Inception -35.69% -33.74%
    12 Months -5.75% -5.09%
    24 Months -27.04% -26.17%
    Last 60 Trading Days -14.26% -14.07%
    Last 75 Trading Days -10.59% -10.35%
    Monthly Returns (through 11/20/24)
    		Return GNOM Return Index
    Nov 2024 -5.31% -5.28%
    Oct 2024 -7.83% -7.80%
    Sep 2024 -1.42% -1.26%
    Aug 2024 -1.88% -1.86%
    Jul 2024 11.10% 11.20%
    Jun 2024 2.86% 2.88%
    May 2024 3.26% 3.28%
    Apr 2024 -13.27% -13.23%
    Mar 2024 -5.41% -5.20%
    Feb 2024 11.62% 11.55%
    Jan 2024 -7.01% -6.90%
    Dec 2023 11.12% 11.12%
    Nov 2023 17.53% 17.71%
    Oct 2023 -12.70% -12.66%
    Sep 2023 -9.53% -9.44%
    Aug 2023 -8.41% -8.28%
    Jul 2023 1.22% 1.27%
    Jun 2023 -0.83% -0.71%
    May 2023 -0.40% 0.01%
    Apr 2023 -0.32% -0.36%
    Mar 2023 -2.40% -2.28%
    Feb 2023 -7.07% -7.73%
    Jan 2023 7.02% 7.13%
    Dec 2022 -5.87% -5.89%
    Nov 2022 2.37% 2.43%

    Total returns take into account management, administration and fees and other costs automatically deducted from the fund's assets. Before investing, you may read the prospectus in the “FEES AND EXPENSES” section for more details.

    NAV & Index Chart

    Top Holdings As of 11/20/24

    Full Holdings (.csv)
    Net Assets (%) Ticker Name Country SEDOL Market Price ($) Shares Held Market Value ($)
    6.14 NTRA NATERA INC United States BYQRG48 167.88 26,220 4,401,813.60
    5.24 VCYT VERACYTE INC United States BFTWZY0 39.20 95,872 3,758,182.40
    4.46 CRSP CRISPR THERAPEUTICS AG United States BDHF4K6 47.26 67,632 3,196,288.32
    4.33 QGEN QIAGEN N.V. United States BMGBZP0 42.09 73,862 3,108,851.58
    4.30 TECH BIO-TECHNE CORP United States BSHZ3Q0 68.72 44,867 3,083,260.24
    4.19 A AGILENT TECHNOLOGIES INC United States 2520153 128.57 23,386 3,006,738.02
    4.17 RNA AVIDITY BIOSCIENCES INC United States BMWHPY1 43.65 68,525 2,991,116.25
    4.07 ARWR ARROWHEAD PHARMA United States BYQBFJ8 18.71 156,177 2,922,071.67
    4.00 ILMN ILLUMINA INC United States 2613990 131.68 21,765 2,866,015.20
    3.99 BNTX BIONTECH SE-ADR United States BK6H543 102.14 28,033 2,863,290.62
    3.96 LEGN LEGEND BIOTECH CORP-ADR United States BMX9K07 40.14 70,786 2,841,350.04
    3.88 BMRN BIOMARIN PHARMAC United States 2437071 62.56 44,456 2,781,167.36
    3.70 SRPT SAREPTA THERAPEUTICS INC United States B8DPDT7 110.86 23,953 2,655,429.58
    3.68 RARE ULTRAGENYX PHARM United States BJ62Z18 46.40 56,885 2,639,464.00
    3.66 ALNY ALNYLAM PHARMACE United States B00FWN1 248.79 10,551 2,624,983.29
    3.60 BEAM BEAM THERAPEUTICS INC United States BK6L288 24.49 105,555 2,585,041.95
    3.00 MRNA MODERNA INC United States BGSXTS3 36.94 58,270 2,152,493.80
    2.97 1548 HK GENSCRIPT BIOTECH CORP Hong Kong BD9Q2J2 1.38 1,542,518 2,128,431.08
    2.74 MYGN MYRIAD GENETICS INC United States 2614153 15.30 128,713 1,969,308.90
    2.72 TXG 10X GENOMICS INC-CLASS A United States BKS3RS7 13.32 146,738 1,954,550.16
    2.69 NTLA INTELLIA THERAPEUTICS INC United States BYZM6C2 13.12 146,991 1,928,521.92
    2.27 CDNA CAREDX INC United States BP3YM74 22.37 72,698 1,626,254.26
    2.24 RCKT ROCKET PHARMACEU United States BDFKQ07 13.04 123,474 1,610,100.96
    2.20 GILD GILEAD SCIENCES INC United States 2369174 88.63 17,832 1,580,450.16
    2.08 VRTX VERTEX PHARM United States 2931034 451.23 3,309 1,493,120.07
    1.22 VIR VIR BIOTECHNOLOGY INC United States BK4PZ38 6.74 129,875 875,357.50
    1.15 MRVI MARAVAI LIFESC-A United States BMCWKZ2 4.82 171,403 826,162.46
    0.91 PACB PACIFIC BIOSCIEN United States B4N8MH9 1.72 377,973 650,113.56
    0.87 RGNX REGENXBIO INC United States BZ0G875 9.63 64,818 624,197.34
    0.79 SGMO SANGAMO THERAPEUTICS INC United States 2573083 1.95 289,646 564,809.70
    0.69 FLGT FULGENT GENETICS INC United States BYQBFQ5 17.28 28,728 496,419.84
    0.62 SANA SANA BIOTECHNOLOGY INC United States BMFJJ97 2.53 177,163 448,222.39
    0.58 VERV VERVE THERAPEUTICS INC United States BNKGXX2 4.55 90,897 413,581.35
    0.57 ALLO ALLOGENE THERAPEUTICS INC United States BFZNYB7 2.05 200,937 411,920.85
    0.52 QURE UNIQURE NV United States BJFSR88 5.70 65,452 373,076.40
    0.40 EDIT EDITAS MEDICINE INC United States BZ8FPH3 2.41 118,628 285,893.48
    0.36 PSTX POSEIDA THERAPEUTICS INC United States BJ4SF41 2.72 94,278 256,436.16
    0.33 CRBU CARIBOU BIOSCIENCES INC United States BNYJR68 1.96 119,714 234,639.44
    0.30 TSVT 2SEVENTY BIO INC United States BMTXV88 3.11 69,956 217,563.16
    0.29 LYEL LYELL IMMUNOPHARMA INC United States BN6MB18 1.03 199,421 205,403.63
    0.13 CASH United States 1.00 90,346 90,346.44
    0.01 E SCILEX HOLDING RESTRICTED United States 9A80I96 0.03 226,071 6,381.98
    0.00 JAPANESE YEN United States 0.01 -1 -0.01
    -0.02 OTHER PAYABLE & RECEIVABLES United States 1.00 -16,285 -16,285.17
    Holdings are subject to change. "Cash" denotes U.S. dollars.

    Sector Breakdown As of 10/31/24

    Sector Weight (%)
    Health Care 91.8
    Energy 8.2

    Source: AltaVista Research, LLC

    Country Breakdown As of 10/31/24

    Country Weight (%)
    United States 76.9
    Italy 8.2
    Germany 4.4
    Netherlands 4.0
    Switzerland 3.2
    China 2.8
    Japan 0.5

    Source: AltaVista Research, LLC

    ETF Characteristics As of 11/20/24

    Return on Equity -16.80%
    Weighted Avg. Market Cap 18,495 M
    2023 2024
    Price-to-earnings -13.96 -14.76
    Price-to-book value 2.27 2.74

    Source: AltaVista Research, LLC

    ETF Risk Stats As of 10/31/24

    Versus Beta
    S&P 500 1.27
    MSCI EAFE 1.12
    MSCI Emg. Mkts 0.89
    Standard Deviation 29.60%

    Source: AltaVista Research, LLC

    ETF Documents

    TERMS OF USE

    Global X Brasil Gestora de Investimentos Ltda. (“Global X Brasil”) is an asset manager authorized by the Brazilian Securities and Exchange Commission (“CVM”), constituted in the form of CVM Resolution No. 21/2021. Investing involves risks. The material on this site is for informational purposes only and does not constitute investment advice, recommendation, offer or solicitation to buy or sell any securities, funds, or strategies to any person in any jurisdiction in which an offer, solicitation, purchase, or sale would be illegal under the securities laws of such jurisdiction. Opinions expressed here are subject to change without notice. Reliance upon the information contained in this material is at the sole discretion of the reader. No securities regulator has confirmed the accuracy of any information contained herein. Access to the information on this site or the use of the services or information provided herein is prohibited by any person or entity in any jurisdiction or country where such distribution or use is contrary to local law, rules, or regulation. Investment in index funds (ETFs) involves risks, including detachment from the benchmark index and related to the liquidity of shares in the secondary market. Investment funds managed by Global X Brasil use strategies that can result in significant equity losses for their quota holders. Global X Brasil, its partners and employees are exempt of responsibility for any damages resulting directly or indirectly from the use of the information contained on this website.

    FOR EVALUATION OF THE PERFORMANCE OF AN INVESTMENT FUND, IT IS RECOMMENDED THE ANALYSIS OF AT LEAST 12 (TWELVE) MONTHS. INVESTMENT FUNDS DO NOT HAVE A GUARANTEE FROM THE ADMINISTRATOR, THE MANAGER, ANY INSURANCE MECHANISM OR CREDIT GUARANTEE FUND – FGC. INVESTMENTS IN FINANCIAL AND CAPITAL MARKETS ARE SUBJECT TO RISKS OF LOSS GREATER THAN THE TOTAL VALUE OF INVESTED CAPITAL. PAST PROFITABILITY DOES NOT REPRESENT A GUARANTEE OF FUTURE PROFITABILITY THE PROFITABILITY DISCLOSED IS NOT NET OF TAXES. READ THE PROSPECTUS, THE FORM OF COMPLEMENTARY INFORMATION, SHEET OF ESSENTIAL INFORMATION AND THE REGULATION BEFORE INVESTING. DESCRIPTION OF THE ANBIMA TYPE AVAILABLE IN THE FORM OF COMPLEMENTARY INFORMATION.

    Back to Top